Author/Editor		Štabuc, Borut; Tepeš, Bojan; Skok, Pavel; Vujasinović, Miroslav; Blinc, Aleš; Čerček, Miha; Tomšič, Matija; Markovič, Saša
Title		Smernice za preprečevanje in zdravljenje neželenih učinkov nesteroidnih protivnetnih in antiagregacijskih učinkovin na prebavila
Translated title		Guidelines for the prevention and management of gastrointestinal adverse effects in patients receiving non- steroidal anti-inflammatory and antiaggregant therapy
Type		članek
Vol. and No.		Letnik 84, št. 1
Publication year		2014
Volume		str. 3-15
ISSN		1581-0224 - Zdravniški vestnik
Language		slv
Abstract		Adverse effects of nonsteroidal antiinflammatory drugs and antiaggregants on gastrointestinal tract can be prevented or reduced by rational prescribing, use of proton pump inhibitors and Helicobacter pylori eradication. Nonsteroidal antiinflammatory drugs should not be used to treat patients with high risk for serious adverse effects on either upper gastrointestinal or cardiovascular system. Proton pump inhibitors in standard oral dosages are used for treatment of dyspepsia or gastric and duodenal erosions and ulcers, caused by nonsteroidal antiinflammatory drug or antiaggregant use. Peptic ulcer hemorrhage is treated with endoscopic hemostasis and proton pump inhibitors (72-hour continuous infusion followed by 4 % 8 week standard dose oral treatment). Patients can be stratified into three groups based on risk for upper gastrointestinal system adverse effects associated with nonsteroidal antiinflammatory drugs or antiaggregants use. Absence of risk factors denotes low-risk patient population, one or two risk factors are associated with medium risk; high-risk patients harbor either three or more risk factors or history of complicated peptic ulcer disease. Helicobacter pylori should be eradicated (if present) in all medium and high-risk patients prior to introduction of nonsteroidal antiinflammatory drugs or antiaggregants and proton pump inhibitors in standard daily dose should be prescribed for the duration of the treatment. Risk of gastrointestinal hemorrhage should be considered when planning invasive cardiovascular procedures or introduction of antiaggregant or anticoagulant treatment. In the context of acute gastrointestinal hemorrhage, antiaggregants should not be discontinued for longer than 7 days and oral anticoagulant therapy should be stopped and converted to low-molecular-weight heparin after complete hemostasis.
Keywords		guidelines side-effects nonsteroidal antiinflammatory drugs priporočila nesteroidne protivnetne učinkovine antiagregacijske učinkovine